Aarti Pharmalabs Limited

Web: aartipharmalabs.com NSE: AARTIPHARM BSE: 543748 SECTOR: Healthcare - Pharmaceuticals & Biotechnology

704 29(-4%)

Volume

97k as on 24, Dec

Open

573

High

580

Low

572

Close

732

VWAP

582

52 Week High

971

52 Week Low

585

Viand Research Rating
Quality Score

00/00

Growth Score

00/00

Valuation Score

00/00

Momentum Score

00/00

Analyst Recommendations

BUY/SELL

Hold | Buy | Strong Buy
Analyst Price Target
-
Market Cap (cr)

6,380

No. of Shares

9.07

P/E

27.47

P/B

3.32

Face Value

5

Div. Yield

-

Book Value (TTM)

-

CASH

-

DEBT

-

EPS (TTM)

-

ROE

12.08

ROCE

-

Profit Growth

-

Listing Date

30-Jan-23

Promoter Holding

43.08%

FII Holding

8.39%

DII Holding

7.4%

Price Chart
Price Performance
1 Week0%
1 Month10%
3 Months11%
6 Months11%
1 Year11%
YTD11%
Moving Average
5 Day SMA574
10 Day SMA588
20 Day SMA612
30 Day SMA0
50 Day SMA0
61 Day SMA0
80 Day SMA0
200 Day SMA0
PIVOT LEVEL
StandardCamarillaFibonacciWoodie's
Resistance 3609585596606
Resistance 2596583587594
Resistance 1587581582584
Pivot Point574579574572
Support 1565577565562
Support 2551575560550
Support 3543573551540
Competitors/Peers
#SymbolMCAPLTP1W1M6M1YP/EInd PEDebt/EqDiv Yld %NP Qtr Rs.Cr.
1SUNPHARMA4,42,18718432%14%2%9%39000
2DIVISLAB1,80,28067912%6%4%1%65000
3TORNTPHARM1,53,28145290%8%18%40%64000
4APOLLOHOSP1,19,04782803%7%12%17%58000
5CIPLA1,14,86914221%10%7%4%22000
6DRREDDY1,11,01513300%1%7%7%20000
7ZYDUSLIFE1,09,37810876%16%15%17%20000
8LUPIN1,04,01722751%2%9%15%23000
9MANKIND1,00,48224343%7%7%2%49000
10MAXHEALTH96,8679957%1%15%14%0000
Load More
Shareholding Pattern (%)
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Promoters(0.01) 43.08%(0.21) 43.10%(-0.81) 42.88%(-0.61) 43.72%(-0.41) 44.29%(-1.51) 44.65%(-0.41) 46.10%(0.01) 46.46%(0.01) 46.46%(0.21) 46.46%(0.31) 46.30%(0.01) 45.98%(0.01) 45.98%
FIIs(0.71) 8.39%(-0.31) 7.69%(0.71) 8.02%(0.01) 7.34%(-1.31) 7.36%(1.31) 8.64%(0.31) 7.38%(-1.31) 7.07%(0.21) 8.33%(-0.31) 8.17%(1.01) 8.45%(-0.31) 7.43%(0.01) 7.69%
DIIs(-0.31) 7.40%(0.71) 7.66%(-0.91) 6.95%(0.31) 7.80%(-2.81) 7.53%(-1.01) 10.36%(-0.11) 11.35%(1.51) 11.47%(0.11) 9.97%(-0.61) 9.91%(-0.11) 10.51%(-3.01) 10.65%(0.01) 13.68%
Government0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public41.10%41.54%42.12%41.12%40.81%36.33%35.17%35.00%35.24%35.45%34.73%35.92%32.64%
No. of Shareholders179,373184,489190,655187,039196,314185,111185,436189,012204,122215,796226,286258,239276,664
Quarterly Results
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Sales583432418386564538458555506449440458485472531457460
Expenses470330344293418409364459388353352373405385441371385
Operating Profit113102749314612994961189688858086908676
OPM %1924182426242017232120191618171916
Other Income14202-2542211010103
Interest171311771065544465645
Depreciation2829252323232120191918171616171414
Profit before tax826339651151017274967467645965696859
Tax %2524282423262425322923262727262418
Net Profit 6148285088745555655352474348515249
EPS in Rs6.745.293.085.469.758.166.036.127.25.825.725.24.735.26000
Profit and Loss
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Sales181921151853194512000
Expenses14501651146716039930
Operating Profit3694643863422070
OPM %20222118170
Other Income15105230
Interest47271721120
Depreciation104877363420
Profit before tax2333613002611550
Tax %25242826210
Net Profit 1752722171931220
EPS in Rs19.2730.0523.9321.3500
Dividend Payout %181713900
Cash Flows
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Cash from Operating Activity0332216250-440
Cash from Investing Activity0-414-215-158-1390
Cash from Financing Activity06510-1632600
Net Cash Flow0-1712-71780
Balance Sheet
Mar 2026Sep 2025Mar 2025Sep 2024Mar 2024Mar 2023Mar 2022Mar 2021
Equity Capital4545454545450.250.25
Reserves20792001194518111712151313860
Borrowings7546594133862852153410
Other Liabilities6035615035335404703120
Total Liabilities34823266290627772582224420400
Fixed Assets152515151137120410339267820
CWIP3051603741161371021870
Investments194187779410787320
Other Assets14571403131913621305113010380
Total Assets34823266290627772582224420400
Delivery
#Date
585
39%
814
Value (Cr)Q/T
16
Del
52
Del
10
127-May655
35
224716
226-May695
35
214315
325-May732
12
14445
422-May713
9
14464
521-May704
6
11523
620-May701
8
14443
719-May706
6
9483
818-May701
7
12423
915-May712
10
12424
1014-May719
7
11383
1113-May707
12
11455
1212-May713
11
10455
1311-May743
14
9527
148-May766
11
11506
157-May778
11
15455
166-May788
23
246816
175-May767
35
225118
184-May806
45
203717
1930-Apr740
39
204116
2029-Apr709
16
15437
2128-Apr712
20
18489
2227-Apr713
15
20558
2324-Apr693
11
15425
2423-Apr689
8
15454
2522-Apr694
12
12516
2621-Apr707
14
18477
2720-Apr676
9
14616
2817-Apr698
7
16594
2916-Apr700
7
9483
3015-Apr703
11
11475
3113-Apr692
15
12447
3210-Apr689
7
14463
339-Apr681
8
12423
348-Apr688
17
15458
357-Apr650
5
10543
366-Apr650
9
12494
372-Apr646
11
12394
381-Apr635
13
12395
3930-Mar592
31
205417
4027-Mar609
25
145413
4125-Mar639
23
125011
4224-Mar623
18
125410
4323-Mar618
17
14519
4420-Mar645
11
15586
Daily Market Cap
DateTotal Market CapChangeChg %
26-May6,380c257c3.87
25-May6,637c185c2.87
22-May6,452c60c0.94
21-May6,391c18c0.28
20-May6,373c37c0.58
19-May6,410c103c1.63
18-May6,308c130c2.01
15-May6,437c108c1.66
14-May6,546c122c1.89
13-May6,424c31c0.48
12-May6,455c322c4.75
11-May6,777c295c4.17
07-May7,071c64c0.90
06-May7,136c92c1.31
05-May7,044c120c1.73
04-May6,924c202c3.00
30-Apr6,722c244c3.76
29-Apr6,478c37c0.58
28-Apr6,441c155c2.47
24-Apr6,286c55c0.87
23-Apr6,342c53c0.84
22-Apr6,289c75c1.18
21-Apr6,364c18c0.29
17-Apr6,346c17c0.26
16-Apr6,363c41c0.64
15-Apr6,404c00
Stock Checklist
Price is below from 52 week high low average: 38%
Stock is trading above all short term SMAs: NO
Stock is trading above all long term SMAs: YES
Stock is Consistently Improving Long Term: NO
FII purchased in last quarter: YES
Promoters are buying the stock: NO
Mutual Fund Holdings
Strategy Builder
Bulk Deals
Events
News
Exchange Filings
Annual Reports
Ratings & Research Reports
Concalls
Announcements
0